9月21日，诺诚健华(09969.HK)盘中上涨5.1%，报15.44港元，成交额1434.43万港元。
消息面上，公司近日自主研发的靶向PSMA和STEAP1的双抗ADC新药ICP-B381获国家药监局批准开展临床试验，用于治疗前列腺癌等实体瘤，系全球首个靶向该双靶点的ADC品种。同时，生物科技板块整体表现强势，英派药业-B涨21.87%、康方生物涨4.03%、信达生物涨3.83%、百济神州涨1.41%，板块联动效应明显。基本面方面，公司上半年营收11.37亿元，同比增长55.46%，归母净利润2.46亿元，同比大增918.69%，持续保持盈利态势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.